European Commission
English

Kohesio: discover EU projects in your region

   
more info
Start date: 1 December 2015
End date: 31 December 2023
Number of projects: 19
Total budget: 167 605 414,88 €
EU contribution: 98 518 898,32 €
Website: n/a
Country: European Commission Flag
Explore more: n/a
funds
ERDF: 98 518 898,32 €

1 - 15 of 19
PROJECTTOTAL BUDGETEU CONTRIBUTIONFUNDDevelopment and implementation of an innovative antiviral therapist in the treatment of COVID-19 and influenza infections in clinical trials and business of its own company 14 448 069,89 € 8 646 688,49 € ERDF Expansion of the structure and research facilities of Celon Pharma S.A. through the construction of the Development Research Centre 17 636 345,78 € 7 936 355,60 € ERDF Serotonergic analgesic therapy based on 5-HT7 receptor agonist (STEP7) 12 362 718,24 € 6 952 120,09 € ERDF Developing an innovative, first-class, low-molecular, double-oriented, immunomodulatory and cytotoxic therapy as a candidate for the treatment of leukaemias and solid tumours 10 171 823,34 € 6 210 229,49 € ERDF In vivo validation, toxicological development and implementation for clinical trials and own company activities, candidate for inhalation drug in the therapy of inflammatory and fibrotic lung diseases including COVID-19 complications 10 435 625,01 € 6 035 665,79 € ERDF Preclinical and clinical development of first class, innovative bispecific immunotherapy as a candidate for cancer immunotherapy 9 708 921,06 € 5 943 395,26 € ERDF Preclinical and clinical development of ubiquitin-proteasom pathway inhibitor as an innovative medicine used in cancer therapy 8 330 144,20 € 5 701 204,43 € ERDF Preclinical and clinical development of innovative GPR40 receptor agonist in the treatment of type II diabetes 8 697 477,55 € 5 486 775,93 € ERDF Development of an innovative Phage Display based platform for the production of bispecific constructs and the development of preclinical and clinical development of an innovative bispecific drug candidate in the treatment of inflammatory diseases. 8 850 982,32 € 5 479 813,37 € ERDF Preclinical and clinical development of an innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases. 8 853 019,70 € 5 449 992,94 € ERDF Development of a CHO cell-based and innovative expressive system of biosimilar production platform and preclinical and clinical development of a biosimilar drug based on the Fab fragment 8 288 030,78 € 5 328 611,09 € ERDF Selective JAK inhibitor in the treatment of immune-mediated diseases 7 750 825,00 € 5 144 702,50 € ERDF Preclinical and clinical development of innovative TrkB agonists in the treatment of nervous system diseases 7 656 642,44 € 5 085 810,52 € ERDF Development and implementation of innovative therapy based on GPR40 receptor agonism in neuropathic pain therapy. 9 405 498,41 € 4 935 420,47 € ERDF Implementation of CELON PHARMA S.A. and development of CPL409116, an innovative inhibitor of JAK and ROCK kinases as an oral drug in the treatment of idiopathic pulmonary fibrosis. 8 093 472,84 € 4 172 448,79 € ERDF